Geneva Biotech is a privately held biotechnology company, based in Geneva, Switzerland. Founded in 2012

News

Intelligent DNA delivery systems

Welcome Guest \\ Login

New News Release



23 September
2020
14:28 | Wednesday

GENEVA BIOTECH CO-FOUNDERS PUBLISH IN SCIENCE GOOD REVIEW IN FORBES

Geneva Biotech co-founders publish in Science good review in Forbes

22 September
2020
14:18 | Tuesday

PRESS RELEASE ON GENEVA BIOTECH’S COVID-19 RESEARCH

Press Release on Geneva Biotech’s COVID-19 research

07 February
2020
08:03 | Friday

PRE-MRNA PROCESSING MACHINERY

Published in Science using MultiBac: the structure of the human histone pre-mRNA 3′-end processing machinery

12 October
2019
05:03 | Saturday

KINETOCHORE NUCLEOSOME STRUCTURE

Published in Nature using MultiBac, the structure of the inner kinetochore CCAN complex assembled onto a centromeric nucleosome

01 October
2019
09:30 | Tuesday

GENEVA BIOTECH REVEALS DRUG DISCOVERY PIPELINE

Geneva Biotech releases information for the first time on their drug discovery pipeline. See Pipeline

04 September
2019
05:08 | Wednesday

INFLUENZA A POLYMERASE STRUCTURE

Published in Nature using MultiBac, the structure of the influenza A virus RNA polymerase gives insight into flu virus replication

10 July
2019
12:48 | Wednesday

T-CELL AND B-CELL TRANSDUCTION TECHNOLOGIES

Geneva Biotech releases the first efficient non-lentiviral transduction system for immortal T-cells and B-cells. Please see Mammalian Product Category “T-Cells B-Cells

03 July
2019
11:57 | Wednesday

KEY CANCER MECHANISM UNCOVERED WITH MULTIBAC

Replication fork protection by BRCA1–BARD1 revealed in Nature

30 May
2019
11:49 | Thursday

POLY(A) TAIL SHORTENING INSIGHTS REVEALED VIA MULTIBAC

The cryo-EM structure of Pan2-Pan3 in complex with a poly(A) RNP published in Cell provides molecular insights into the process of poly(A) tail shortening

29 May
2019
11:41 | Wednesday

REGULATION OF BRISC–SHMT2 UNLOCKED WITH MULTIBAC

BRISC–SHMT2 interactions are key to immune regulation as revealed in Nature

24 September
2018
00:00 | Monday

LEADING BACULOVIRAL GENOMES

Many of Geneva Biotech’s industry leading baculoviral genomes are now available as competent cells in Europe, Asia, and North America !

11 April
2018
11:21 | Wednesday

INO80-NUCLEOSOME COMPLEX SOLVED WITH MULTIBAC

Structure and regulation of key chromatin remodelling enzyme INO80 revealed in Nature

26 March
2018
17:24 | Monday

DISRUPTIVE DISCOVERY METHOD FOR INHIBITORS OF PROTEIN-PROTEIN INTERACTIONS

Protein-Protein interactions (PPIs) are central to most essential cellular mechanisms including gene expression, protein translocation, cell cycle progression and signal transduction. Bellón-Echeverría et al. published in Scientific Reports a proof of concept employing MultiBacMam to identify new small-molecule inhibitors of the CDK5-p25 protein-protein interaction. The method is generally applicable to any multiprotein cascade important in drug discovery.

23 March
2018
17:20 | Friday

13 LAB INTERNATIONAL BENCHMARKING STUDY NAMES EMBACY THE WORLD’S BEST BACULOVIRUS

Stolt-Bergner et al. published in Journal of Structural Biology a benchmarking initiative in 13 independent labs to compare the world’s leading baculovirus expression systems. Geneva Biotech’s EMBacY virus was ranked #1 in performance.

12 March
2018
10:33 | Monday

EBOLA RNA POLYMERASE PRODUCED USING MULTIBAC

Tchesnokov et al. published in Scientific Reports a production system for Ebola Virus RNA-Dependent RNA Polymerase Complex using the MultiBac system, providing a powerful discovery system for this key drug target.

27 November
2017
16:12 | Monday

LARGE DNA CARGO GENOME ENGINEERING PROJECT

Geneva Biotech and Sphere Fluidics launch R&D project to develop methods that enable large DNA cargo delivery and genome engineering in primary cells that have proven refractory to traditional transfection, electroporation, or transduction methods. LINK

21 October
2017
16:11 | Saturday

NEW SYNBAC DEVELOPMENT MILESTONE

Geneva Biotech and partners have recorded >70% increase in baculovirus DNA stability in scale up experiments to 100L using second generation SynBac genomes. DNA stability was found to strongly correlate (r = 0.91) with expression yield of multiple different test proteins.

21 July
2017
17:41 | Friday

COMPETENT CELL PARTNER IN NORTH AMERICA

IG-Logo

Intact Genomics is a world leader of ultra-high competent cell production and BAC (bacterial artificial chromosome) library related technologies. Intact has partnered with Geneva Biotech to offer North American customers competent cells containing Geneva Biotech’s viral genomes. See their Geneva Biotech partnered products here INTACT GENOMICS

07 January
2017
16:10 | Saturday

MTORC1 STRUCTURE SOLVED USING MULTIBAC

The Ban lab published in Science the structure of key drug target mTORC1 using the MultiBac system, providing critical information on the function and intricate regulation of this important enzyme which is implicated in common human diseases including cancer and diabetes.

13 January
2016
11:14 | Wednesday

LAUNCH OF KINASE FACTORY™

Developed by the European Union ComplexINC R&D consortium, Kinase Factory™ is a baculovirus expression system where entire 5-8 protein chaperone machineries specific for protein kinase folding were integrated into synthetic baculovirus genomes to provide a unique platform for production of kinases that display poor folding or stability. The system is also ideal for boosting production yields of kinases for large scale expression, e.g. for target production for drug discovery.

23 December
2015
11:12 | Wednesday

LAUNCH OF HORMONE RECEPTOR FACTORY™

Developed by the European Union ComplexINC R&D consortium, Hormone Receptor Factory™ is a baculovirus expression system where entire 5-7 protein chaperone machineries specific for hormone folding were integrated into synthetic baculovirus genomes to provide a unique platform for production of hormone receptors that display poor folding or stability. The system is also ideal for boosting production yields of hormone receptors for large scale expression, e.g. for target production for drug discovery.

23 February
2015
11:11 | Monday

LAUNCH OF COMPLEXLINK™

Developed at the European Molecular Biology Laboratory (EMBL), ComplexLink™ is a system of polyprotein production combined with co-production of sequence-specific proteases that co-translationally cleave the polyprotein into functional monomeric subunits. The technology provides unique advantages over existing expression systems for production of multiprotein complexes where subunit stoichiometry is difficult to control. The technology was applied to produce recombinant influenza polymerase complex from a self-processing polyprotein, as recently published in Nature.

01 December
2014
12:55 | Monday

EMBL GRANTS GENEVA BIOTECH EXCLUSIVE LICENSE ON MINIMIZED SYNTHETIC VIRAL GENOMES

The European Molecular Biology Laboratory (EMBL), Europe's flagship laboratory for basic research in molecular biology, has granted Geneva Biotech an exclusive license for intellectual property covering minimal baculoviral genomes. These genomes were  created using modern synthetic biology techniques, and will appear in future as products "SynBac".

25 November
2014
21:49 | Tuesday

CTI GRANT FOR SMALL MOLECULE DISCOVERY PROGRAM

The Swiss Commission for Technology and Innovation (CTI) awards Geneva Biotech and Partner University of Geneva CHF 977k for development of an early stage drug discovery program in cellular signaling.

CTI Banner

18 November
2014
23:18 | Tuesday

COMPLEXLINK™ TECHNOLOGY CATALYZES INFLUENZA R&D

The influenza polymerase remained inaccessible for decades – the challenge to produce this highly complicated protein complex for detailed analysis, proved to be a seemingly insurmountable technical challenge. The break-through studies, lead by Stephen Cusack, renowned influenza expert and Head of the EMBL Grenoble Outstation, used Geneva Biotech's ComplexLinkTM technology to produce recombinant influenza polymerase complex from a self-processing polyprotein, as recently published in Nature.

FluPol

22 March
2014
20:20 | Saturday

GENEVA BIOTECH USA

Geneva Biotech has launched a subsidiary in Indianapolis, Indiana to provide better services to our US-based clients.

GBiotech USA

03 March
2014
12:30 | Monday

MULTICOLI™ TECHNOLOGY KEY TO UNRAVELLING MOLECULAR BIOLOGY MYSTERY

Membrane proteins constitute a large and important fraction of the proteome, with 80% of the druggable targets in cells being membrane proteins. The holotranslocon, a large transmembrane multiprotein complex comprising seven subunits catalyzes the entry of proteins into cell membranes. EMBL and UK based scientists used the MultiColi™ expression system in the ComplexINC R&D consortium to engineer a tightly regulated multigene co-expression circuit which enabled the functional assembly of holotranslocon complex published in the early edition of the Proceedings of the National Academy USA.

molecular_biology

02 December
2013
12:11 | Monday

COMPLEXINC LARGE SCALE EUROPEAN UNION COLLABORATIVE GRANT

Geneva Biotech joins the ComplexINC R&D consortium for development of cutting edge new protein expression technologies.

ComplexINC

01 November
2013
12:13 | Friday

SYNSIGNAL LARGE SCALE EUROPEAN UNION R&D COLLABORATIVE GRANT

Geneva Biotech joins the SynSignal R&D consortium for development of the next generation of synthetic biology tools and technologies.

SynSignal

28 July
2013
11:43 | Sunday

LAUNCH OF VLP FACTORY™ EXPRESSION SYSTEM

VLP Factory™ constitutively secretes promiscuous virus matrix proteins, with built in functionality to allow you to introduce multiple additional expression cassettes for production of multiprotein VLPs.

27 July
2013
12:27 | Saturday

LAUNCH OF MULTIMAM STABLE™

Developed as a variant of our transient mammalian multiprotein expression system, MultiMam Stable™ allows for easy DNA recombination-based assembly of multiprotein expression cassettes, followed by chromosomal integration and copy number expansion.

06 June
2013
16:41 | Thursday

LAUNCH OF SWEETBAC™

Developed through a collaboration between the University of Vienna and the European Molecular Biology Laboratory (EMBL), SweetBac™ is the world’s first baculovirus that produces humanized glycosylation patterns on recombinantly expressed proteins. SweetBac™ provides unique advantages over existing baculovirus expression systems for i) production of targets for drug discovery and assay development ii) antibody development against membrane proteins like GPCRs and ion channels, and iii) manufacturing of biologics in insect cells with humanized glycosylation patterns.

06 January
2013
11:02 | Sunday

MULTIBAC™ USED TO PRODUCE ANOTHER MASSIVE PROTEIN COMPLEX

The Berger Laboratory from EMBL Grenoble have described in molecular detail the architecture of the central scaffold of TFIID: the human protein complex essential for transcription from DNA to mRNA. The study, published today in Nature, opens new perspectives in the study of transcription and of the structure and mechanism of other large multi-protein assemblies involved in gene regulation. MultiBac™ has now been used in more than a dozen Nature and Science publications in the last 3 years.

latestnews1

06 August
2012
11:02 | Monday

EMBL GRANTS EXCLUSIVE TECHNOLOGY LICENSE TO GENEVA BIOTECH

The European Molecular Biology Laboratory (EMBL), Europe's flagship laboratory for basic research in molecular biology, has granted Geneva Biotech an exclusive license for intellectual property covering a portfolio of protein expression technologies. The company has also concluded a research collaboration agreement with EMBL.

Research Highlights

our r&d View all

Latest News

GENEVA BIOTECH CO-FOUNDERS PUBLISH IN SCIENCE GOOD REVIEW IN FORBES Geneva Biotech co-founders publish in Science good review in Forbes ...

View all

    Contact Us



      //